Objective: The article examines the objective, findings, and clinical context described in FDA approves first NPC survival treatment. Approach: Approval populat
The FDA approved adrabetadex (Lembaz) as the first treatment shown to reduce mortality risk in Niemann-Pick disease type C.
Approval covers adults and children weighing at least 7 kg whose neurological symptoms began before age 6.
In a nonrandomized analysis, median overall survival was 102 months with adrabetadex and 59 months in matched external controls, with a 55% lower relative risk of death.
Adrabetadex carries a boxed warning for hearing impairment, including permanent hearing loss, and requires audiological evaluations before treatment and during dose escalation.
Adrabetadex is administered intrathecally every 2 weeks by or under the supervision of a clinician experienced in lumbar punctures.
Objective: To examine associations between reproductive history and hormone therapy use and brain small vessel disease (SVD), white matter integrity, and Alzhei
Objective: To assess refractive and astigmatic outcomes after PRK in eyes with moderate or high preoperative astigmatism and identify factors associated with re
Objective: The article examines the objective, findings, and clinical context described in First Gaucher type 3 neurological drug approved. Approach: Approval:
The FDA approved venglustat (Infilbray) for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg.
Venglustat crosses the blood-brain barrier and inhibits glucosylceramide synthase, reducing glucosphingolipid accumulation.
Approval was supported by a 52-week randomized trial of 43 patients aged 12 years or older with stable systemic disease after enzyme replacement therapy.
At week 52, venglustat improved a combined neurological assessment compared with enzyme replacement therapy, but the FDA announcement provided no numerical effect estimates.
Reported adverse effects included gastrointestinal symptoms and mood changes; serious psychiatric risks included suicidal ideation and behavior.
Objective: To examine sleep-start experiences and their associations with sleep, psychological, and demographic characteristics in adults. Approach: Design and
In a cross-sectional online survey of 194 adults, 96 reported sleep starts at least weekly, defined by sudden awakenings at sleep onset and at least 1 additional symptom.
Weekly sleep starts were associated with poorer sleep quality, greater insomnia severity, stronger dysfunctional sleep-related beliefs, and higher anxiety symptoms.
Poorer sleep quality, stronger dysfunctional sleep-related beliefs, higher anxiety symptoms, and younger age were independently associated with more frequent sleep starts.
Participants described varied experiences, including muscle jerks, dream-like sensations, falling sensations, palpitations, and emotional responses such as alarm and anxiety.
Because the study relied on retrospective self-reports and a cross-sectional design, it could not establish causality or distinguish sleep starts reliably from related sleep-onset phenomena.
Objective: The article summarizes four reports: a case of a swallowed spoon requiring surgery, a mouse study of dietary cellulose and nanoplastic exposure, a re
Surgeons removed an 18-cm spoon lodged in a 28-year-old man’s duodenum for nearly 3 months; he later required surgery for adhesive small bowel obstruction.
In male mice, a 50% cellulose diet was associated with greater nanoplastic excretion and less intestinal accumulation than diets containing 5% or 15% cellulose.
A review of 10 studies involving 365 adults found that odors sometimes affected postural control, but evidence certainty ranged from moderate to very low.
In a 13-year cohort study of 1,708 adults, moderate tea consumption was generally associated with more favorable bone measurements, but the study could not establish causation.
The nanoplastic findings came from male mice fed fiber concentrations exceeding typical human diets, and the researchers said human studies are needed.
Objective: The article examines the objective, findings, and clinical context described in Making Pediatric Leukemia Testing Accessible. Approach: Current testi
Objective: The article describes point-of-care (POC) testing for sexually transmitted infections, including available assays, potential benefits, and the role o
Point-of-care STI tests provide results near the site of care, typically within minutes to an hour, enabling clinical decisions during the same visit.
FDA-cleared, CLIA-waived molecular assays can detect chlamydia and gonorrhea in about 20 minutes, with accuracy approaching laboratory-based testing.
Same-visit results can reduce dependence on follow-up, which is especially important for people facing barriers to care or at increased risk of being lost to follow-up.
Point-of-care testing may reduce empiric treatment and unnecessary antibiotic exposure, while supporting antimicrobial stewardship.
Implementation challenges include cost, operational complexity, specimen-type restrictions, workflow demands, and the need for staff training and quality oversight.
Objective: To assess whether postoperative suction drains are associated with blood loss, transfusion, length of stay, or complications after primary total hip
Objective: The article examines the objective, findings, and clinical context described in FDA approves neladalkib for ALK-positive lung cancer. Approach: Appro
The FDA granted accelerated approval to neladalkib for adults with locally advanced or metastatic ALK-positive NSCLC after specified prior targeted therapy.
Eligible patients had received alectinib as their only prior ALK TKI in the advanced setting or at least 2 ALK TKIs and platinum-based chemotherapy.
In ALKOVE-1, the confirmed overall response rate was 49% among 67 patients previously treated only with alectinib and 32% among 155 patients in the other treatment group.
Among responders, 76% and 52% in the alectinib-only group maintained responses for at least 6 and 12 months, respectively; corresponding rates in the other group were 69% and 51%.
Neladalkib is taken orally at 150 mg once daily; warnings include hepatotoxicity, renal and ocular toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity.
Objective: The article examines the objective, findings, and clinical context described in A Faster Route to Antibody Peptide Maps. Approach: Workflow: The meth
Objective: To assess whether an AI model can detect pancreatic cancer-associated changes in CT scans before the disease is clinically diagnosed. Approach: Model
The Mayo Clinic-developed REDMOD analyzed subtle pancreatic tissue changes in CT scans that were not visible to experienced radiologists.
The study evaluated 1,462 CT scans, including 219 from patients who later developed pancreatic cancer and 1,243 from individuals without the disease.
In independent testing, REDMOD detected 73% of patients who later developed cancer, compared with 39% detected by radiologists; the median interval to diagnosis was 475 days.
REDMOD maintained 68% sensitivity in scans obtained more than 2 years before diagnosis, while external validation showed specificity ranging from 81% to 88%.
The retrospective study did not establish whether earlier detection improves survival, and prospective validation is needed; the model also incorrectly flagged about 1 in 5 cancer-free individuals.
Objective: To evaluate the efficacy and safety of mivocabtagene autoleucel in adults with antibody-positive stiff person syndrome (SPS) who had responded inadeq
Agentic AI can retrieve information, coordinate tasks, assemble evidence, and flag risks while people retain responsibility for scientific decisions.
In clinical development, agents can combine historical recruitment, eligibility, and site-capability data to prepare feasibility assessments for expert review.
Agents can monitor study startup and execution, identify missing operational inputs, track recruitment and protocol adherence, and escalate emerging risks.
In pharmacovigilance and regulatory work, agents can assemble case information and submission materials, draft content, and flag missing data or inconsistencies.
Effective use depends on well-designed workflows, connected data, human review, and governance that documents agent outputs, evidence, risks, and human decisions.
Objective: Develop a human stem cell-derived model that reproduces key features of lens development for research into lens biology and disease. Approach: Organo
Researchers used SEAM differentiation and lens-optimized medium to generate human induced pluripotent stem cell-derived lens organoids, or lentoids, over 8 weeks.
Compared with conventional ocular differentiation medium, optimized cultures produced larger and more numerous lentoids with increased expression of lens-associated genes.
Expression of CRYGA and CRYGB increased approximately 63-fold and 59-fold, respectively, while connexins CX46 and CX50 and N-cadherin also increased.
Electron microscopy showed elongated fibre-like cells, epithelial layers, capsule-like structures, and intercellular junctions resembling features of the human lens.
Isolated lentoids generated proliferating lens epithelial-like cells that expressed PAX6, SIX3, and SOX2 and later formed secondary lentoids; optical testing and further maturation assessments remain
Objective: Develop a human stem cell-derived model that reproduces key features of lens development for research into lens biology and disease. Approach: Organo
Researchers used SEAM differentiation and lens-optimized medium to generate human induced pluripotent stem cell-derived lens organoids, or lentoids, over 8 weeks.
Compared with conventional ocular differentiation medium, optimized cultures produced larger and more numerous lentoids with increased expression of lens-associated genes.
Expression of CRYGA and CRYGB increased approximately 63-fold and 59-fold, respectively, while connexins CX46 and CX50 and N-cadherin also increased.
Electron microscopy showed elongated fibre-like cells, epithelial layers, capsule-like structures, and intercellular junctions resembling features of the human lens.
Isolated lentoids generated proliferating lens epithelial-like cells that expressed PAX6, SIX3, and SOX2 and later formed secondary lentoids; optical testing and further maturation assessments remain